糖尿病、药物性肝损伤与脓毒症对代谢功能障碍相关脂肪性肝病相关慢加急性肝衰竭结局的影响
研究基于亚太肝病学会ACLF研究联盟注册数据,将258例MAFLD-ACLF患者按70:30随机分为推导队列和验证队列(111例),主要终点为90天死亡率。推导队列中糖尿病占27%、药物性肝损伤占29%、脓毒症占23%,90天生存率为51%。在MELD-Na和AARC评分基础上加入糖尿病和非病毒性诱因构建的MAFLD-MELD-Na与MAFLD-AARC评分,在两个队列中均优于标准评分。
要点
- MAFLD-ACLF患者90天生存率仅51%,近半数在90天内死亡。
- 糖尿病、非病毒性诱因、胆红素、INR和肝性脑病是死亡的独立影响因素。
- 新评分MAFLD-MELD-Na(糖尿病+12、非病毒性诱因+12)和MAFLD-AARC(各+5)预测效能优于标准评分。
核心结论
- 近半数MAFLD-ACLF患者在90天内死亡;糖尿病及药物性肝损伤、脓毒症等非病毒性诱因导致不良结局。
- 新构建的MAFLD-MELD-Na和MAFLD-AARC评分可为MAFLD-ACLF患者提供可靠的90天死亡率预测。
研究设计与样本
- 从亚太肝病学会ACLF研究联盟(AARC注册)招募MAFLD-ACLF患者,排除合并酒精、乙型肝炎病毒、丙型肝炎病毒等其他慢性肝病病因者。
- 数据按70:30随机分为推导队列(n=258)和验证队列(n=111),主要终点为90天死亡率,仅纳入基线临床、实验室特征和严重度评分。
主要发现
- 推导队列258例,男性60%,平均年龄53岁,糖尿病27%,高血压29%。
- 主要诱因包括病毒性肝炎(甲型和戊型肝炎病毒,32%)、药物性肝损伤(29%)和脓毒症(23%)。
- 入院时MELD-Na和AARC评分平均分别为32±6和10.4±1.9,90天生存率为51%。
- 非病毒性诱因、糖尿病、胆红素、国际标准化比值和肝性脑病是影响死亡率的独立因素。
关键数值与推荐
- MAFLD-MELD-Na评分:在MELD-Na基础上糖尿病加12分、非病毒性诱因加12分。
- MAFLD-AARC评分:在AARC基础上糖尿病加5分、非病毒性诱因加5分。
- 两个新评分在推导队列和验证队列中均优于标准评分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) and its complication, MAFLD-related acute-on-chronic liver failure (MAFLD-ACLF), is rising. Yet, factors determining patient outcomes in MAFLD-ACLF remain understudied. METHODS: Patients with MAFLD-ACLF were recruited from the Asian Pacific Association for the Study of the Liver-ACLF Research Consortium (AARC registry). The diagnosis of MAFLD-ACLF was made when the treating unit had identified the etiology of chronic liver disease as MAFLD (or previous nomenclature such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, or non-alcoholic steatohepatitis-cirrhosis). Patients with coexisting other etiologies of chronic liver disease (such as alcohol, hepatitis B virus, hepatitis C virus, etc.) were excluded. Data were randomly split into derivation (n = 258) and validation (n = 111) cohorts at a 70:30 ratio. The primary outcome was 90-day mortality. Only the baseline clinical, laboratory features and severity scores were considered. RESULTS: The derivation group had 258 patients; 60% were male, with a mean age of 53. Diabetes was noted in 27% and hypertension in 29%. The dominant precipitants included viral hepatitis (hepatitis A virus and hepatitis E virus, 32%), drug-induced injury (drug-induced liver injury, 29%), and sepsis (23%). Model for End-Stage Liver Disease-Sodium (MELD-Na) and AARC scores on admission averaged 32 ± 6 and 10.4 ± 1.9. At 90 days, 51% survived. Nonviral precipitant, diabetes, bilirubin, international normalized ratio, and encephalopathy were independent factors influencing mortality. Adding diabetes and precipitant to MELD-Na and AARC scores, the novel MAFLD-MELD-Na score (+12 for diabetes, +12 for nonviral precipitant), and MAFLD-AARC score (+5 for each) were formed. These outperformed the standard scores in both cohorts. DISCUSSION: Almost half of patients with MAFLD-ACLF die within 90 days. Diabetes and nonviral precipitants such as drug-induced liver injury and sepsis lead to adverse outcomes. The new MAFLD-MELD-Na and MAFLD-AARC scores provide reliable 90-day mortality predictions for patients with MAFLD-ACLF.
引用
- Kumar A, Arora A, Choudhury A, et al. Impact of Diabetes, Drug-Induced Liver Injury, and Sepsis on Outcomes in Metabolic Dysfunction Associated Fatty Liver Disease-Related Acute-on-Chronic Liver Failure. Am J Gastroenterol. 2024. PMID: 39016385. doi:10.14309/ajg.0000000000002951
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。